Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endoscopic Gastric Mucosal Ablation (GMA) as a Primary Obesity Therapy Early Feasibility [COMET EF] - Step II

NCT05486338 is registered in ClinicalTrials.gov with Erbe Elektromedizin GmbH as lead sponsor.

NCT NCT05486338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05486338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endoscopic Gastric Mucosal Ablation (GMA) as a Primary Obesity Therapy Early Feasibility [COMET EF] - Step II
Lead sponsor
Erbe Elektromedizin GmbH
Phase
Not applicable
Overall status
Completed
Start date
September 5, 2023
Completion date
July 18, 2025
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adiposity, obesity